- Algernon Pharmaceuticals (AGN) has announced a four-for-one stock split of its issued and outstanding common shares
- The shares will begin trading on a split basis on March 3, 2023
- Algernon Pharmaceuticals is a Canadian clinical-stage drug development and repurposing company
- Algernon Pharmaceuticals (AGN) is up 1.19 per cent on the day, trading at C$1.70 per share at 3:45 pm ET
Algernon Pharmaceuticals (AGN) has announced a four-for-one stock split of its issued and outstanding common shares.
Each Algernon shareholder of record will receive three additional shares for each share held.
The shares will begin trading on a split basis on March 3, 2023.
Upon completion of the split, there will be approximately 9,653,724 shares issued and outstanding.
Algernon Pharmaceuticals is a Canadian clinical-stage drug development and repurposing company investigating multiple drugs for unmet global medical needs.
Algernon Pharmaceuticals (AGN) is up 1.19 per cent on the day, trading at C$1.70 per share at 3:45 pm ET.